S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
OTCMKTS:PMCB

PharmaCyte Biotech Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.02
$0.03
52-Week Range
$0.00
Now: $0.02
$0.05
Volume9.73 million shs
Average Volume24.08 million shs
Market Capitalization$51.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PMCB
CUSIPN/A
Phone917-595-2850
Employees4
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-3,830,000.00

Miscellaneous

Outstanding Shares2,341,410,000
Market Cap$51.75 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1583rd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

165th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.02
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PMCB News and Ratings via Email

Sign-up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PharmaCyte Biotech (OTCMKTS:PMCB) Frequently Asked Questions

What stocks does MarketBeat like better than PharmaCyte Biotech?

Wall Street analysts have given PharmaCyte Biotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PharmaCyte Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PharmaCyte Biotech?

PharmaCyte Biotech saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 260,800 shares, an increase of 327.5% from the January 28th total of 61,000 shares. Based on an average daily trading volume, of 25,343,500 shares, the short-interest ratio is currently 0.0 days.
View PharmaCyte Biotech's Short Interest
.

When is PharmaCyte Biotech's next earnings date?

PharmaCyte Biotech is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for PharmaCyte Biotech
.

How has PharmaCyte Biotech's stock price been impacted by COVID-19 (Coronavirus)?

PharmaCyte Biotech's stock was trading at $0.0450 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PMCB stock has decreased by 50.9% and is now trading at $0.0221.
View which stocks have been most impacted by COVID-19
.

Who are PharmaCyte Biotech's key executives?

PharmaCyte Biotech's management team includes the following people:
  • Mr. Kenneth L. Waggoner, Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 73, Pay $316.67k)
  • Mr. Carlos A. Trujillo CPA, CPA, CFO & Director (Age 63, Pay $250k)
  • Dr. Gerald W. Crabtree, Chief Scientific Officer & Director (Age 80, Pay $109.67k)
  • Dr. José L. Iglesias, Consulting Chief Medical Officer
  • Dr. Hans-Peter Hammes, Member of Medical & Scientific Advisory Board and Consultant

Who are some of PharmaCyte Biotech's key competitors?

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX).

What is PharmaCyte Biotech's stock symbol?

PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PharmaCyte Biotech's stock price today?

One share of PMCB stock can currently be purchased for approximately $0.02.

How much money does PharmaCyte Biotech make?

PharmaCyte Biotech has a market capitalization of $51.75 million.

How many employees does PharmaCyte Biotech have?

PharmaCyte Biotech employs 4 workers across the globe.

What is PharmaCyte Biotech's official website?

The official website for PharmaCyte Biotech is www.pharmacyte.com.

Where are PharmaCyte Biotech's headquarters?

PharmaCyte Biotech is headquartered at 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653.

How can I contact PharmaCyte Biotech?

PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The company can be reached via phone at 917-595-2850 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.